Elosulfase alfa is a Recombinant Enzyme owned by BioMarin Pharmaceutical, and is involved in 9 clinical trials, of which 7 were completed, and 2 are ongoing.

Elosulfase alfa is an enzyme replacement therapy of N-acetylgalactosamine-6 sulfatase (GALNS) which is needed to break down glycosaminoglycans (GAGs) that gradually build up in mucopolysaccharidosis. The replacement enzyme helps to break down GAGs and stop them accumulating in the body, relieving the symptoms of the disease.

The revenue for Elosulfase alfa is expected to reach a total of $13.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Elosulfase alfa NPV Report.

Elosulfase alfa is originated and owned by BioMarin Pharmaceutical.

Elosulfase alfa Overview

Elosulfase alfa (Vimizim) is an enzyme replacement therapy that comprises of N-acetylgalactosamine-6 sulfatase (GALNS). It is formulated as concentrate solution and solution for injection for intravenous route of administration. Vimizim is indicated for the treatment of mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). Elosulfase alfa, which is a purified human enzyme produced by recombinant DNA technology in a Chinese hamster ovary cell line.

BioMarin Pharmaceutical Overview

BioMarin Pharmaceutical (BioMarin) develops and commercializes innovative medicines for the treatment of rare genetic diseases and medical conditions such as Duchenne muscular dystrophy (DMD), phenylketonuria (PKU), achondroplasia, late infantile neuronal ceroid lipofuscinosis (CLN2) and hemophilia A. The company focuses on developing breakthrough treatments for debilitating and life-threatening diseases. Its product category consists of multiple clinical and preclinical offerings which include Naglazyme-Mucopolysaccharidosis Type VI (MPS VI), Aldurazyme-MPS I and others. The company operates through its manufacturing facilities in Novato, California. It conducts business operations in the US, Europe, Latin America, the Middle East, and Asia-Pacific. BioMarin is headquartered in San Rafael, California, the US.

The company reported revenues of (US Dollars) US$1,846.3 million for the fiscal year ended December 2021 (FY2021), a decrease of 0.8% over FY2020. The operating loss of the company was US$82.3 million in FY2021, compared to an operating loss of US$36.8 million in FY2020. The net loss of the company was US$64.1 million in FY2021, compared to a net profit of US$859.1 million in FY2020. The company reported revenues of US$505.3 million for the third quarter ended September 2022, a decrease of 5.3% over the previous quarter.

Quick View – Elosulfase alfa

Report Segments
  • Innovator (NME)
Drug Name
  • Elosulfase alfa
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Genetic Disorders
Key Companies
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.